Goldman Sachs Group Inc Editas Medicine, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,167,194 shares of EDIT stock, worth $2.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,167,194
Previous 1,218,687 4.23%
Holding current value
$2.56 Million
Previous $5.69 Million 30.07%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$3.39 - $5.96 $174,561 - $306,898
-51,493 Reduced 4.23%
1,167,194 $3.98 Million
Q2 2024

Aug 13, 2024
SELL
$4.67 - $7.28 $851,084 - $1.33 Million
-182,245 Reduced 13.01%
1,218,687 $5.69 Million
Q1 2024

May 15, 2024
BUY
$7.03 - $11.07 $5.95 Million - $9.37 Million
846,858 Added 152.84%
1,400,932 $10.4 Million
Q4 2023

Feb 13, 2024
BUY
$6.25 - $11.11 $680,843 - $1.21 Million
108,935 Added 24.47%
554,074 $5.61 Million
Q3 2023

May 14, 2024
SELL
$6.92 - $9.31 $753,830 - $1.01 Million
-108,935 Reduced 19.66%
445,139 $3.47 Million
Q3 2023

Nov 14, 2023
SELL
$6.92 - $9.31 $1.09 Million - $1.46 Million
-157,045 Reduced 26.08%
445,139 $3.47 Million
Q2 2023

May 14, 2024
SELL
$6.36 - $11.47 $660,625 - $1.19 Million
-103,872 Reduced 14.71%
602,184 $4.96 Million
Q2 2023

Aug 14, 2023
SELL
$6.36 - $11.47 $660,625 - $1.19 Million
-103,872 Reduced 14.71%
602,184 $4.96 Million
Q1 2023

May 14, 2024
SELL
$7.03 - $11.53 $1.38 Million - $2.26 Million
-196,093 Reduced 21.74%
706,056 $5.12 Million
Q1 2023

May 11, 2023
SELL
$7.03 - $11.53 $1.38 Million - $2.26 Million
-196,093 Reduced 21.74%
706,056 $5.12 Million
Q4 2022

May 14, 2024
SELL
$8.32 - $13.21 $1.78 Million - $2.82 Million
-213,574 Reduced 19.14%
902,149 $8 Million
Q4 2022

Feb 13, 2023
SELL
$8.32 - $13.21 $1.78 Million - $2.82 Million
-213,574 Reduced 19.14%
902,149 $8 Million
Q3 2022

May 14, 2024
BUY
$12.16 - $19.42 $3.99 Million - $6.37 Million
328,003 Added 41.64%
1,115,723 $13.7 Million
Q3 2022

Nov 10, 2022
BUY
$12.16 - $19.42 $3.99 Million - $6.37 Million
328,003 Added 41.64%
1,115,723 $13.7 Million
Q2 2022

May 14, 2024
BUY
$9.99 - $21.35 $2.33 Million - $4.99 Million
233,646 Added 42.17%
787,720 $9.32 Million
Q2 2022

Aug 15, 2022
BUY
$9.99 - $21.35 $1.52 Million - $3.25 Million
152,171 Added 23.94%
787,720 $9.32 Million
Q1 2022

May 16, 2022
SELL
$14.08 - $27.63 $4.92 Million - $9.66 Million
-349,605 Reduced 35.49%
635,549 $12.1 Million
Q4 2021

Feb 14, 2022
SELL
$26.55 - $40.57 $10.7 Million - $16.3 Million
-401,275 Reduced 28.94%
985,154 $26.2 Million
Q3 2021

Nov 10, 2021
BUY
$39.27 - $72.94 $54.4 Million - $101 Million
1,386,429 New
1,386,429 $57 Million

Others Institutions Holding EDIT

# of Institutions
248
Shares Held
57M
Call Options Held
410K
Put Options Held
394K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $151M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email